<DOC>
	<DOCNO>NCT02839291</DOCNO>
	<brief_summary>To evaluate current medical practice influence health-related quality life , patient treat injectable bone antiresorptive drug ( biphosphonates denosumab ) least one year .</brief_summary>
	<brief_title>Evaluation Medical Practice Management Bone Metastases After Injectable Bone Antiresorptive Treatment , Its Influence Quality Life</brief_title>
	<detailed_description>This protocol evaluate pursuit injectable bone antiresorptive treatment switch oral biphosphonates , treatment stop , contexte medical practice . The primary end-point health-related quality life ( QoL ) . Secondary endpoint safety , overall survial , impact toxicity treatment QoL , description supportive care .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<criteria>Patient histologically proven tumor bone metastasis , single multiple ( without metastasis extraosseous ) Patients treat injectable bone antiresorptive therapy 12 month Signed write informed consent patient medical psychiatric condition disease would make patient inappropriate complete quality life questionaries patient guardianship , curator protection justice , pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>